Showing results (21-30 of 34) with videos related to
Sort By:
Pageof 4
Nature Genetics|November 19, 2013
High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemiasJoshua J Waterfall, Evgeny Arons, Robert L Walker, et al.Blood|October 8, 2025
Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemiaBrett Schroeder, Constance M Yuan, Hao-Wei Wang, et al.Blood Neoplasia|June 24, 2025
COVID-19 vaccination in patients with classic and variant hairy cell leukemiaRobert J Kreitman, Lacey James, Julie Feurtado, et al.Blood Advances|September 20, 2023
COVID-19 in patients with classic and variant hairy cell leukemiaRobert J Kreitman, Theresa Yu, Lacey James, et al.Plos One|February 11, 2020
Expression of the muscle-associated gene MYF6 in hairy cell leukemiaEvgeny Arons, Hong Zhou, Mark Sokolsky, et al.Blood|September 15, 2022
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemiaRobert J Kreitman, Philippe Moreau, Farhad Ravandi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2020
Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell LeukemiaDai Chihara, Evgeny Arons, Maryalice Stetler-Stevenson, et al.Blood|December 24, 2024
Non-V600E BRAF mutations and treatment for hairy cell leukemiaEvgeny Arons, Chin-Hsien Tai, Joshi Suraj, et al.Blood Advances|October 4, 2021
Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variantDai Chihara, Evgeny Arons, Maryalice Stetler-Stevenson, et al.Leukemia|June 18, 2025
Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemiaFilippo Vit, Tamara Bittolo, Antonella Zucchetto, et al.Pageof 4